Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and ...

Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...

Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Shares of Viking Therapeutics, Inc. (VKTX) were gaining around 17 percent in the pre-market activity on the Nasdaq after the company ...

Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Viking Therapeutics (VKTX – Research ...

Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...

Viking Therapeutics (Nasdaq: VKTX) reported promising early results for its experimental obesity pill, VK2735, with increased ...

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...